Hovione’s Inhaler for High-Dose Delivery Earns Product Design Award

Drug Development & Delivery, April 16, 2020

8Shot Dry Powder Inhaler (DPI) | Hovione

Hovione Technology recently announced its innovative 8Shot Dry Powder Inhaler (DPI) enabling high-dose drug delivery to the lungs has received the Red Dot 2020 Product Design Award in the Healthcare Daily Living AIDS category. The Red Dot Design Award is an internationally recognized quality seal awarded for innovative and high-quality product design.

“The Red Dot jury’s experience and expertise evaluating outstanding product design and technical innovation for more than 60 years is unparalleled. This distinction awarded to our 8Shot DPI is a great success for Hovione Technology”, said Peter Villax, Hovione Technology’s CEO.

8Shot is the world’s first 8-puff, disposable DPI enabling drug delivery of new pharmaceutical compounds requiring very high doses delivered to the lungs. It delivers therapeutic doses up to 400 mg formulated as drug alone or engineered particles in multiple, sequential inhalation maneuvers for maximum therapeutic benefit and patient safety.

“We are extremely proud and delighted to accept the Red Dot Product Design Award, together with our design and development partner WeADD,” said Dr João Ventura Fernandes, Hovione Technology’s Director of Technology Development and Licensing. “The 8Shot™ DPI is uniquely positioned to make available off-the-shelf to pharmaceutical companies a patented high payload DPI to deliver inhaled biologics, antibiotics, anti-virals, vaccines, pain or rescue treatments requiring high-dose drug delivery.”

Hovione Technology’s TwinMax and 8Shot dry powder inhalers are designed to enable safe and effective delivery of large doses to the lung. Featuring patented inhaler technology, TwinMax and 8Shot are compatible with drug doses up to 100 mg and 400 mg respectively, delivered conveniently to patients from multiple inhalations. Our Large Dose DPIs are suitable for inhaled delivery of biologics, antibiotics, anti-viral, vaccines, pain or rescue treatments.

Hovione Technology offers access to a complete portfolio of innovative, cost-effective dry powder inhalation devices – disposable, capsule-based, blister-based and large dose DPIs. With over 20 years of expertise developing innovative inhaler technology, Hovione Technology’s team has been behind the first market approved disposable dry powder inhaler for influenza treatment in Japan, the TwinCaps DPI. Millions of patients are being treated every year with Hovione Technology’s innovative inhaler technology. For more information, visit www.hovionetechnology.com

WeADD is a Portuguese Company specialized in innovation, development, product engineering and intelligent property in small and large appliances, machinery, functional packaging and consumer electronics in sectors such as health, sports, coffee and internet of things. For more information, visit www.weadd.com

Read the article at DDD

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process. Read the full article at gmp-journal.com

Article

GMP Journal, 04 March 2024

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024

Browser not supported

Press Room

Hovione’s Inhaler for High-Dose Delivery Earns Product Design Award

Also in the Press Room

Continuous Tableting and the Road to Global Adoption

Hovione Macau awarded by the Government of Macau at a Ceremony held in Macau

Also in Events

CPhI India 2024